Cerevance Reports the P-III (ARISE) Trial Data on Solengepras in Parkinson’s Disease

Shots: Cerevance has reported the P-III (ARISE) trial data assessing solengepras (75 or 150mg, QD, PO) vs PBO as an adjunct to levodopa & other PD medications in 341 PD pts (≥30yrs.) with motor fluctuations & ≥3hrs. of daily OFF time (91% pts completed the trial) Solengepras (150mg) met the 1EP, reducing average daily OFF time…

ByRidhi RastogiOctober 8, 2026

NEWS

Kairos Pharma Reports Positive Interim P-II Data for ENV-105 in Metastatic Prostate Cancer

Shots: Kairos Pharma announced positive interim efficacy data from its ongoing P-II study evaluating ENV-105 (carotuximab) in combination with apalutamide in pts. with metastatic castration-resistant prostate cancer (mCRPC) The combination demonstrated a statistically significant improvement in progression-free survival, with median PFS of 17.7 mons. vs 2 mons. with apalutamide alone (P=0.0008) Following the interim results,…

ByPrince GiriOctober 6, 2026

NEWS

AbbVie and Genmab Report Positive Data from the P-III Study of Epcoritamab Plus R-CHOP in Newly Diagnosed DLBCL

Shots: AbbVie and Genmab announced positive topline results from the P-III (EPCORE DLBCL-2) study, demonstrating a statistically significant and clinically meaningful improvement in PFS vs R-CHOP alone (SoC) in newly diagnosed diffuse large B-cell lymphoma (DLBCL) pts. with an IPI score of 2-5 The study evaluated fixed treatment duration epcoritamab(SC) plus rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and…

ByPrince GiriOctober 6, 2026

NEWS

Johnson & Johnson Reports P-III (ICONIC-TOTAL) Trial Data on Icotyde for Difficult-to-Treat Plaque Psoriasis

Shots: J&J has reported the 2yr. P-III (ICONIC-TOTAL) trial data assessing Icotyde vs PBO for the treatment of PsO in pts with at least moderate severity affecting special areas (e.g., scalp, genital, &/or hands and feet) Icotyde maintained durable skin clearance, with IGA 0/1 rates increasing from 57% at Wk. 16 to 67% at Wk.…

ByRidhi RastogiOctober 5, 2026

NEWS

BI Reports P-III (SYNCHRONIZE-2) Trial Data on Survodutide for Obesity/Overweight and Type 2 Diabetes at EASD 2026

Shots: P-III trial of survodutide (3.6 or 6mg, QW) in 755 pts, met both co-1EP using treatment-regimen & efficacy estimands. At Wk. 76, weight loss reached up to an average of 13.1% vs 3.1% with PBO, while up to 79.3% vs 32.7% pts achieved ≥5% weight loss (efficacy estimand) In 2EPs, trial showed reduced HbA1c…

ByRidhi RastogiOctober 1, 2026

NEWS

Merck Reports the P-IIb (MK-7240-012) Trial Data on Tulisokibart in Hidradenitis Suppurativa

Shots: Merck has presented the P-IIb (MK-7240-012) study data assessing tulisokibart vs PBO in pts with moderate to severe hidradenitis suppurativa at EADV’26 Trial met its 1EP, with HiSCR50 at Wk. 16 achieved by 72% pts on high-dose tulisokibart (480mg, Q2W) & 64% on medium-dose (480mg, Q4W), representing a 37% & 29% improvement over PBO…

ByRidhi RastogiOctober 1, 2026

NEWS

Vanda Pharmaceuticals Reports the P-III Trial Results on Hetlioz in Delayed Sleep-Wake Phase Disorder

Shots: Vanda Pharmaceuticals has reported the P-III (VP-VEC-162-3502) trial data assessing Hetlioz (tasimelteon; 20mg, PO, QD; n=20) vs PBO (n=20) in 43 adults with Delayed Sleep-Wake Phase Disorder (DSWPD) Trial met its 1EP, showing Hetlioz (20mg) shifted the time of sleep onset 42.5 min. earlier vs 5.4 min. shift on PBO, plus in an exploratory…

ByRidhi RastogiSeptember 30, 2026

NEWS

Takeda Reports P-III (LATITUDE) Program Results on Zasocitinib for Plaque Psoriasis

Shots: Takeda has presented the P-III (LATITUDE) studies data assessing zasocitinib (TAK-279) in adults with mod. to sev. plaque psoriasis (PsO) at EADV’26 In P-III (LATITUDE Atlas) study, zasocitinib was superior to deucravacitinib across 1 & all key 2EPs, with complete skin clearance emerging as early as Wk. 8 & 36.5% vs 13.9% pts achieving…

ByRidhi RastogiSeptember 30, 2026

NEWS

Eli Lilly Reports P-III (TRIUMPH-2) Results on Retatrutide for Obesity and Type 2 Diabetes

Shots: TRIUMPH-2 assessed retatrutide (4, 9, or 12mg, QW) vs PBO in 1152 pts with T2D & obesity/overweight, with trial using a stepwise dose-escalation approach at Q4W. Lilly plans to file BLA in Q1’27 At 80wks., avg. body weight reductions were 12.7% (4mg), 19.1% (9mg), & 20.8% (12mg) vs 4%, plus A1C reduced by 1.4%,…

ByRidhi RastogiSeptember 30, 2026

NEWS

Kodiak Sciences Reports P-III (DAYBREAK) Trial Data on Zenkuda and Tabirafusp-ted for wAMD

Shots: Kodiak has reported the P-III (DAYBREAK) trial data assessing Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in parallel vs aflibercept in pts with wet age-related macular degeneration (wAMD) Zenkuda met its 1EP, showing meaningful vision gains & rapid, sustained retinal drying, with 54% of pts achieving 6mos. durability at Yr. 1. tabirafusp-ted also met its vision…

ByRidhi RastogiSeptember 29, 2026

Cerevance Reports the P-III (ARISE) Trial Data on Solengepras in Parkinson’s Disease

Kairos Pharma Reports Positive Interim P-II Data for ENV-105 in Metastatic Prostate Cancer

AbbVie and Genmab Report Positive Data from the P-III Study of Epcoritamab Plus R-CHOP in Newly Diagnosed DLBCL

Johnson & Johnson Reports P-III (ICONIC-TOTAL) Trial Data on Icotyde for Difficult-to-Treat Plaque Psoriasis

BI Reports P-III (SYNCHRONIZE-2) Trial Data on Survodutide for Obesity/Overweight and Type 2 Diabetes at EASD 2026

Merck Reports the P-IIb (MK-7240-012) Trial Data on Tulisokibart in Hidradenitis Suppurativa

Vanda Pharmaceuticals Reports the P-III Trial Results on Hetlioz in Delayed Sleep-Wake Phase Disorder

Takeda Reports P-III (LATITUDE) Program Results on Zasocitinib for Plaque Psoriasis

Eli Lilly Reports P-III (TRIUMPH-2) Results on Retatrutide for Obesity and Type 2 Diabetes

Kodiak Sciences Reports P-III (DAYBREAK) Trial Data on Zenkuda and Tabirafusp-ted for wAMD

Contact US

FOLLOW US